The effects of intravitreal ranibizumab, aflibercept or dexamethasone implant injections on intraocular pressure changes

ArticleAçık Erişim

Özet

Background: The aim of this study was to compare the alterations in intraocular pressure (IOP) values during the early postoperative period after intravitreal ranibizumab, aflibercept, or dexamethasone implant injections. Material/Methods: In this retrospective study, a total of 188 patients were grouped into 3 groups: the ranibizumab group, the aflibercept group, and the dexamethasone group. Ocular axial length (AXL) and anterior chamber depth (ACD) were measured in the pre-injection period. IOP was measured just before the injection at 1 minute,10 minutes, 1 hour, 1 day, and 1 month after injection. Results: There was a transient peak in the ranibizumab group and the aflibercept group at 1 minute that started to decrease at 10 minutes and IOP values returned to preoperative values at approximately 1 hour. Similar alterations were also determined for the dexamethasone group with a lesser increase noted. In the correlation analysis, only alterations in IOP levels at 1 minute were negatively correlated with preoperative AXL values. There was not any correlation between preoperative AXL or ACD values and IOP alterations at any other time points. Conclusions: There was a sudden, transient increase in IOP values after intravitreal ranibizumab or aflibercept injections; which return to normal values in a short time without requirement of any medical treatments. This transient peak was determined to be negatively correlated with the preoperative AXL. © Med Sci Monit,.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/14341Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.12659/msm.910923Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorKarakurt, Yucel
dc.contributor.authorUcak, Turgay
dc.contributor.authorTaslı, Gamze
dc.contributor.authorAgcayazı, Burcu
dc.contributor.authorİcel, Erel
dc.contributor.authorYılmaz, Hayati
dc.date.accessioned2026-10-18T20:29:08.494855557Z
dc.date.available2026-10-18T20:29:08.494855557Z
dc.date.issued2018
dc.description.abstractBackground: The aim of this study was to compare the alterations in intraocular pressure (IOP) values during the early postoperative period after intravitreal ranibizumab, aflibercept, or dexamethasone implant injections. Material/Methods: In this retrospective study, a total of 188 patients were grouped into 3 groups: the ranibizumab group, the aflibercept group, and the dexamethasone group. Ocular axial length (AXL) and anterior chamber depth (ACD) were measured in the pre-injection period. IOP was measured just before the injection at 1 minute,10 minutes, 1 hour, 1 day, and 1 month after injection. Results: There was a transient peak in the ranibizumab group and the aflibercept group at 1 minute that started to decrease at 10 minutes and IOP values returned to preoperative values at approximately 1 hour. Similar alterations were also determined for the dexamethasone group with a lesser increase noted. In the correlation analysis, only alterations in IOP levels at 1 minute were negatively correlated with preoperative AXL values. There was not any correlation between preoperative AXL or ACD values and IOP alterations at any other time points. Conclusions: There was a sudden, transient increase in IOP values after intravitreal ranibizumab or aflibercept injections; which return to normal values in a short time without requirement of any medical treatments. This transient peak was determined to be negatively correlated with the preoperative AXL. © Med Sci Monit,.
dc.identifier.doi10.12659/msm.910923
dc.identifier.eissn1643-3750
dc.identifier.endpage9025
dc.identifier.issn1234-1010
dc.identifier.pmcidPMC6301255
dc.identifier.pmid30542050
dc.identifier.scopus2-s2.0-85058591515
dc.identifier.startpage9019
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/14341
dc.identifier.volume24
dc.identifier.wosWOS:000453264500001
dc.language.isoen
dc.publisherInternational Scientific Information, Inc.
dc.relation.ispartofMedical Science Monitor
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAxial length, eye
dc.subjectIntraocular pressure
dc.subjectIntravitreal injections
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAngiogenesis Inhibitors
dc.subjectAntibodies, Monoclonal, Humanized
dc.subjectDexamethasone
dc.subjectFemale
dc.subjectHumans
dc.subjectMacular Degeneration
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPostoperative Care
dc.subjectRanibizumab
dc.subjectReceptors, Vascular Endothelial Growth Factor
dc.subjectRecombinant Fusion Proteins
dc.subjectRetrospective Studies
dc.subjectVascular Endothelial Growth Factor A
dc.subjectVisual Acuity
dc.subjectaflibercept
dc.subjectangiogenesis inhibitor
dc.subjectfusion protein
dc.subjectmonoclonal antibody
dc.subjectvasculotropin A
dc.subjectvasculotropin receptor
dc.subjectadult
dc.subjectage related macular degeneration
dc.subjectangiography
dc.subjectanterior eye chamber depth
dc.titleThe effects of intravitreal ranibizumab, aflibercept or dexamethasone implant injections on intraocular pressure changes
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus12
rdl.citation.wos9
rdl.departmentDepartment of Ophthalmology, Erzincan University, Faculty of Medicine, Erzincan, Turkey. | Department of Ophthalmology, Erzincan Mengücek Gazi Education and Research Hospital, Erzincan, Turkey.
rdl.oa.statusgold
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)